Tirofiban After Tenecteplase in Stroke

Adjunctive tirofiban was linked to higher rates of positive 90-day outcomes in acute ischemic stroke.

By
Kathryn Wighton
May 14, 2026
6 min

MDSpire News

Objective:

To evaluate the efficacy of adjunctive intravenous tirofiban in patients with acute ischemic stroke who had an inadequate early clinical response to intravenous tenecteplase, specifically focusing on those with NIHSS scores of 4 or higher.

Key Findings:

Functional independence (mRS 0-2) occurred in 79% of tirofiban patients vs. 72% in placebo, but this difference was not statistically significant.

Interpretation:

Tirofiban may improve functional outcomes in patients with inadequate response to tenecteplase, but results from adjusted analyses were not statistically significant, warranting caution in interpretation.

Limitations:

All participants were Chinese, which may limit applicability to other populations, particularly given known differences in intracranial atherosclerosis burden.

Conclusion:

Early intravenous tirofiban may be a potential adjunctive treatment following tenecteplase in select patients with limited clinical response, but generalizability of the findings should be approached with caution.

Tirofiban After Tenecteplase in Stroke

Objective:

Key Findings:

Interpretation:

Limitations:

Conclusion:

Original Source(s)

Tirofiban After Tenecteplase in Stroke

Related Content

External validation of machine learning models for predicting prehospital delay in acute ischemic stroke: a retrospective cohort study

Commentary: Identifying key predictors of post-stroke depression and cognitive impairment in acute stroke survivors

Baptist Health Brain & Spine Care to Host 14th Annual Miami Neuroscience Symposium Nov. 4-6, Bringing Leading Experts Together to Explore Advances in Brain and Spine Care